Wednesday, June 10, 2026
🇺🇸 FDA

pharma · Ulcerative Colitis · Multiple Myeloma

AbbVie Deutschland GmbH

AbbVie Deutschland GmbH & Co. KG

AbbVie Deutschland GmbH clinical programs — 33 development programs from ClinicalTrials.gov with phase, modality, indication, and trial identifiers.

Website Investor relations
Wiesbaden, DE HQ
2018 Founded
101 Employees
EMA registrant Type
Company details
Status
Public
HQ
Wiesbaden, DE
Founded
2018
Employees
101
Programs
102
Drugs
119
Patents
23
Official website ↗ All projects Drug pipeline Patents News & analysis
Intelligence · Clinical Programs

AbbVie Deutschland GmbH projects

33 ClinicalTrials.gov programs sponsored by AbbVie Deutschland GmbH.

AbbVie Deutschland GmbH has 33 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.

All phases Phase III Phase II Phase I NDA / BLA filed Approved programs

33 programs

Clinical programs

  1. -, Pred Forte 10 mg/ml colirio en suspensión

    AbbVie Deutschland GmbH & Co. KG

    platinum-resistant advanced high-grade epithelial ovarian, primary peritoneal, or fallopian tube cancers.

    phase 2 small molecule active

    1 trial

  2. ABBV-066, Lutikizumab

    AbbVie Deutschland GmbH & Co. KG

    Psoriatic Arthritis

    phase 2 small molecule active

    1 trial

  3. IMGN151-1001

    AbbVie Deutschland GmbH & Co. KG

    Recurrent endometrial cancer, recurrent epithelial ovarian, fallopian tube, and primary peritoneal cancer (EOC), recurrent cervical cancer

    phase 2 small molecule active

    1 trial

  4. IMGN632-0802

    AbbVie Deutschland GmbH & Co. KG

    CD123 positive Acute Myeloid Leukemia

    phase 2 small molecule active

    1 trial

  5. IMGN853-0424

    AbbVie Deutschland GmbH & Co. KG

    Recurrent Ovarian Cancer with High Folate Receptor-Alpha Expression

    phase 2 small molecule active

    1 trial

  6. M15-654

    AbbVie Deutschland GmbH & Co. KG

    Multiple Myeloma

    phase 2 small molecule active

    1 trial

  7. M16-109

    AbbVie Deutschland GmbH & Co. KG

    Myelofibrosis

    phase 2 small molecule active

    1 trial

  8. M19-965

    AbbVie Deutschland GmbH & Co. KG

    HIV infection

    phase 2 small molecule active

    1 trial

  9. M22-132

    AbbVie Deutschland GmbH & Co. KG

    B-cell Non-Hodgkin's lymphoma, diffuse large B-cell lymphoma

    phase 2 small molecule active

    1 trial

  10. M23-422

    AbbVie Deutschland GmbH & Co. KG

    Neovascular age-related macular degeneration

    phase 2 small molecule active

    1 trial

  11. M23-703

    AbbVie Deutschland GmbH & Co. KG

    Ulcerative Colitis

    phase 2 small molecule active

    1 trial

  12. M24-147

    AbbVie Deutschland GmbH & Co. KG

    Hepatocellular Carcinoma

    phase 2 small molecule active

    1 trial

  13. M24-209

    AbbVie Deutschland GmbH & Co. KG

    Light Chain Amyloidosis

    phase 2 other active

    1 trial

  14. M24-311

    AbbVie Deutschland GmbH & Co. KG

    Colorectal Cancer

    phase 2 small molecule active

    1 trial

  15. M24-533

    AbbVie Deutschland GmbH & Co. KG

    Metastatic Colorectal Cancer

    phase 2 small molecule active

    1 trial

  16. M24-536

    AbbVie Deutschland GmbH & Co. KG

    Advanced or Metastatic Non-Squamous NSCLC

    phase 2 small molecule active

    1 trial

  17. M24-555

    AbbVie Deutschland GmbH & Co. KG

    Multiple Myeloma

    phase 2 small molecule active

    1 trial

  18. M24-633

    AbbVie Deutschland GmbH & Co. KG

    Small Cell Lung Cancer

    phase 2 small molecule active

    1 trial

  19. M24-885

    AbbVie Deutschland GmbH & Co. KG

    Moderate to Severe Crohn’s Disease

    phase 2 small molecule active

    1 trial

  20. M24-977

    AbbVie Deutschland GmbH & Co. KG

    Adenocarcinoma of the gastroesophageal junction

    phase 2 small molecule active

    1 trial

  21. M25-056

    AbbVie Deutschland GmbH & Co. KG

    Rheumatoid Arthritis

    phase 2 small molecule active

    1 trial

  22. M25-059

    AbbVie Deutschland GmbH & Co. KG

    Multiple Myeloma

    phase 2 small molecule active

    1 trial

  23. M25-204

    AbbVie Deutschland GmbH & Co. KG

    Urothelial Carcinoma, Metastatic Urothelial Carcinoma

    phase 2 small molecule active

    1 trial

  24. M25-275

    AbbVie Deutschland GmbH & Co. KG

    Multiple Myeloma (MM).

    phase 2 small molecule active

    1 trial

  25. M25-709

    AbbVie Deutschland GmbH & Co. KG

    Ovarian Cancer

    phase 2 small molecule active

    1 trial

  26. MEDI0618, Placebo to match MEDI0618

    AbbVie Deutschland GmbH & Co. KG

    Migraine

    phase 2 small molecule active

    1 trial

  27. PCYC-1146-IM

    AbbVie Deutschland GmbH & Co. KG

    Chronic Graft Versus Host Disease (cGVHD)

    phase 2 small molecule active

    1 trial

  28. PIVEKIMAB SUNIRINE

    AbbVie Deutschland GmbH & Co. KG

    Acute Myeloid Leukemia and other blood cancers

    phase 2 small molecule active

    1 trial

  29. Placebo for ABBV-142

    AbbVie Deutschland GmbH & Co. KG

    Idiopathic Pulmonary Fibrosis

    phase 2 small molecule active

    1 trial

  30. Telisotuzumab Vedotin

    AbbVie Deutschland GmbH & Co. KG

    Non-Small Cell Lung Cancer

    phase 2 small molecule active

    1 trial

  31. Telisotuzumab adizutecan

    AbbVie Deutschland GmbH & Co. KG

    Colorectal Cancer

    phase 2 small molecule active

    1 trial

  32. Telisotuzumab adizutecan

    AbbVie Deutschland GmbH & Co. KG

    Locally Advanced or Metastatic Solid Tumours that harbour MET Amplification gene

    phase 2 small molecule active

    1 trial

  33. Upadacitinib, Upadacitinib

    AbbVie Deutschland GmbH & Co. KG

    Crohn's Disease (CD)

    phase 2 small molecule active

    1 trial

Frequently asked questions

How many clinical projects does AbbVie Deutschland GmbH have?

33 published programs are linked to this sponsor in our ClinicalTrials.gov index.

Is this the complete company pipeline?

This directory lists published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.